Literature DB >> 27817804

A comparison of five surveys that identify individuals at risk for airflow obstruction and chronic obstructive pulmonary disease.

Folarin Sogbetun1, William L Eschenbacher2, Jeffrey A Welge3, Ralph J Panos4.   

Abstract

BACKGROUND: The predictive characteristics of different screening surveys for the recognition of individuals at risk for airflow obstruction (AFO) have not been evaluated simultaneously in the same population.
PURPOSE: To compare five AFO/COPD screening questionnaires.
METHODS: 383 individuals completed the Veterans Airflow Obstruction Screening Questionnaire, Personal Level Screener for COPD (VAFOSQ), the 11-Q COPD Screening Questionnaire (11-Q), the COPD Population Screener (COPD-PS) and the Lung Function Questionnaire (LFQ) and performed spirometry. AFO was defined as forced expiratory volume in one second divided by the forced vital capacity (FEV1/FVC) < 0.7, fixed ratio (FR) or FEV1/FVC < lower limit of normal (LLN). The predictive characteristics of the five questionnaires were calculated and non-parametric receiver operating characteristic (ROC) curves estimated by logistic regression.
RESULTS: 376 participants completed at least two of the questionnaires and performed technically acceptable spirometry. AFO was present in 102 (27.1%) and 150 (39.9%) based on LLN and FR, respectively. The number of individuals positively selected by the VAFOSQ was 227, PLS 128, 11-Q 236, COPD-PS 217, and LFQ 328. The area under the ROC curves for the questionnaires was between 0.60 and 0.66 (LLN) and 0.58 and 0.66 (FR).
CONCLUSIONS: Although these screening surveys have acceptable and similar predictive ability for the identification of AFO, their published thresholds lead to substantially different classification rates. The choice of an appropriate threshold for the identification of individuals with possible AFO/COPD should consider the underlying prevalence of AFO/COPD in the target population and the relative costs of misclassifying affected and unaffected cases. CLINICAL TRIAL REGISTRATION: None. PRIMARY SOURCE OF FUNDING: Veterans Health Administration. Published by Elsevier Ltd.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Questionnaire; Screening

Mesh:

Year:  2016        PMID: 27817804     DOI: 10.1016/j.rmed.2016.09.010

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  5 in total

1.  Evaluation of symptomatic patients without airflow obstruction: back to the future.

Authors:  Jose Luis Lopez-Campos; Bernardino Alcazar
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

2.  Self-reported COPD Medication Use and Adherence in the COPD Foundation Patient- Powered Registry Network.

Authors:  Cara B Pasquale; Radmila Choate; Gretchen McCreary; Richard A Mularski; William Clark; MaryEllen Houlihan; Elisha Malanga; Barbara P Yawn
Journal:  Chronic Obstr Pulm Dis       Date:  2021-10-28

3.  Quantification of inaccurate diagnosis of COPD in primary care medicine: an analysis of the COACH clinical audit.

Authors:  María Abad-Arranz; Ana Moran-Rodríguez; Enrique Mascarós Balaguer; Carmen Quintana Velasco; Laura Abad Polo; Sara Núñez Palomo; Jaime Gonzálvez Rey; Ana María Fernández Vargas; Antonio Hidalgo Requena; Jose Manuel Helguera Quevedo; Marina García Pardo; Jose Luis Lopez-Campos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-06-06

4.  Performance and Clinical Utility of Various Chronic Obstructive Pulmonary Disease Case-Finding Tools.

Authors:  Chiung-Zuei Chen; Chau-Chyun Sheu; Shih-Lung Cheng; Hao-Chien Wang; Meng-Chih Lin; Wu-Huei Hsu; Kang-Yun Lee; Diahn-Warng Perng; Hen-I Lin; Ming-Shian Lin; Sheng-Hao Lin; Jong-Rung Tsai; Chin-Chou Wang; Cheng-Yi Wang; Tsung-Ming Yang; Ching-Lung Liu; Tsai-Yu Wang; Ching-Hsiung Lin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-12-18

5.  Performance of COPD population screener questionnaire in COPD screening: a validation study and meta-analysis.

Authors:  Yanhui Gu; Ying Zhang; Qian Wen; Yao Ouyang; Yongchun Shen; He Yu; Chun Wan; Jing Zhu; Fuqiang Wen
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.